HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
Pipeline

Krazati fails confirmatory trial in colorectal cancer, putting approval at risk

Bristol Myers Squibb’s cancer drug Krazati has failed its confirmatory study in second-line colorectal cancer, a company spokesperson confirmed to Endpoints News. Krazati had received accelerated approval in 2024 in this setting. But a Phase ...

By Endpoints News · Apr 30, 2026 · via Endpoints News
Krazati fails confirmatory trial in colorectal cancer, putting approval at risk

Image: Endpoints News

This is an aggregated industry headline. Read the full story at Endpoints News →

Tags
pipelineformat:headlineheadlineEndpoints News
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from Pipeline
All Pipeline →
AstraZeneca's camizestrant ambitions stumble as FDA panel rejects novel oral SERD proposal
PipelineFierceBiotech ↗
AstraZeneca's camizestrant ambitions stumble as FDA panel rejects novel oral SERD proposal
An FDA expert panel on Thursday voted 6 to 3 against AstraZeneca's proposal of using its oral SERD camizestran…
May 2, 2026
Axsome Wins Second Auvelity Approval, Targeting Alzheimer’s Agitation
PipelineBriefing
Axsome Wins Second Auvelity Approval, Targeting Alzheimer’s Agitation
FDA authorizes Auvelity for agitation tied to Alzheimer’s disease, positioning Axsome’s NMDA/sigma-1 modulator…
May 2, 2026
Arvinas’ ‘Protac’ breast cancer drug cleared by FDA
PipelineBioPharma Dive ↗
Arvinas’ ‘Protac’ breast cancer drug cleared by FDA
Known as Veppanu, the drug is the first of its kind to get to market. But Arvinas and partner Pfizer are still…
May 1, 2026